We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.8%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.57B
AUM Growth
+$1.06B
Cap. Flow
+$745M
Cap. Flow %
7.79%
Top 10 Hldgs %
36.3%
Holding
159
New
27
Increased
34
Reduced
20
Closed
32

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$202M
2
COO icon
Cooper Companies
COO
+$180M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.3M
4
SHPG
Shire pic
SHPG
+$77.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$75.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$240M
2
VTRS icon
Viatris
VTRS
+$184M
3
AGN
Allergan Inc
AGN
+$107M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$89.3M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0.07%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANGO icon
126
CALL
AngioDynamics
ANGO
$597M
– –
-200,000
Closed -$3.27M
BMRN icon
127
BioMarin Pharmaceuticals
BMRN
$12B
– –
-1,435,400
Closed -$89.3M
CERS icon
128
CALL
Cerus
CERS
$577M
– –
-500,000
Closed -$2.08M
CPRX
129
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,895,000
Closed -$4.79M
IBB icon
130
PUT
iShares Biotechnology ETF
IBB
$9.5B
– –
-450,000
Closed -$38.6M
INSM icon
131
Insmed
INSM
$22.7B
– –
-538,500
Closed -$10.8M
IRWD icon
132
CALL
Ironwood Pharmaceuticals
IRWD
$602M
– –
-358,200
Closed -$4.6M
JAZZ icon
133
CALL
Jazz Pharmaceuticals
JAZZ
$16.1B
– –
-150,000
Closed -$22.1M
LAB icon
134
CALL
Standard BioTools
LAB
$322M
– –
-250,000
Closed -$7.35M
PTCT icon
135
PTC Therapeutics
PTCT
$6.2B
– –
-178,100
Closed -$4.66M
TEVA icon
136
CALL
Teva Pharmaceuticals
TEVA
$39.4B
– –
-100,000
Closed -$5.24M
VNDA icon
137
Vanda Pharmaceuticals
VNDA
$303M
– –
-455,000
Closed -$7.36M
VTRS icon
138
CALL
Viatris
VTRS
$20.8B
– –
-100,000
Closed -$5.16M
ZTS icon
139
Zoetis
ZTS
$33B
– –
-229,000
Closed -$7.39M
VCRA
140
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-447,500
Closed -$5.91M
XLRN
141
DELISTED
Acceleron Pharma
XLRN
– –
-171,800
Closed -$5.84M
NXTM
142
DELISTED
NxStage Medical Inc.
NXTM
– –
-795,200
Closed -$11.4M
ANTH
143
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-116,594
Closed -$3.16M
STJ
144
CALL
DELISTED
St Jude Medical
STJ
– –
-125,000
Closed -$8.66M
ZGNX
145
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-25,950
Closed -$417K
RNA
146
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
– –
-264,000
Closed -$3.33M
CBST
147
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-90,000
Closed -$6.28M
ITMN
148
DELISTED
INTERMUNE INC
ITMN
– –
-5,425,200
Closed -$240M
QCOR
149
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-100,000
Closed -$9.25M
QCOR
150
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-125,000
Closed -$11.6M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2014 Portfolio in Review

As of Q3 2014, OrbiMed held 159 positions worth $9.57B, up 12% from $8.52B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed deployed $745M of net new capital in Q3 2014, opening 27 new positions and adding to 34 existing holdings. Its largest new stake was Cooper Companies: 4,570,800 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Viatris, an estimated $184M trimmed.

  • OrbiMed's largest Q3 2014 buy was Cooper Companies: 4,570,800 shares worth $178M.
  • OrbiMed added most to Allergan plc in Q3 2014, an estimated $202M increase.
  • OrbiMed's biggest Q3 2014 reduction was Viatris, cutting an estimated $184M.
  • OrbiMed fully exited INTERMUNE INC in Q3 2014, selling an estimated $240M.
  • OrbiMed's ten largest holdings make up 36% of its $9.57B portfolio in Q3 2014.
  • OrbiMed opened 27 new positions and closed 32 in Q3 2014.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $9.57B.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.